Senti Biosciences: Chardan Capital keeps Buy rating, raises PT to $12.

Senti Biosciences: Chardan Capital keeps Buy rating, raises PT to $12.

Chardan Capital has maintained its Buy rating for Senti Biosciences (SNTI) while raising its price target to $12.00 per share. This update comes after Laidlaw analysts initiated coverage on Senti Biosciences with a similar positive outlook, setting a price target of $15.00 and expressing confidence in the company's innovative CAR-NK therapy, SENTI-202 [1].

Senti Biosciences is an early to mid-clinical stage biotechnology firm focused on developing SENTI-202, a novel CAR-NK therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML). The company recently reported promising interim results from its Phase I trial at the American Association for Cancer Research (AACR) meeting, which have sparked optimism among analysts [1].

Chardan Capital's decision to raise the price target reflects its belief in Senti Biosciences' potential for future clinical advancements and the differentiated approach of SENTI-202. The firm's analysts noted the therapy's potential to offer a unique treatment option for high-risk r/r AML patients [2].

The increase in the price target aligns with other analyst ratings. Laidlaw analysts, who initiated coverage on Senti Biosciences with a Buy rating and a $15.00 price target, also cited the company's strong pipeline and promising clinical trial results [1]. Additionally, Wall Street analysts forecast an average one-year price target of $12.00, implying an upside of 237.08% from the current price of $3.56 [2].

Senti Biosciences has been actively advancing its clinical programs and strengthening its leadership team. The company recently appointed Dr. James B. Trager to its Scientific Advisory Board and granted stock options to three new employees, including Jay Cross, the new Chief Financial Officer [1]. These moves highlight the company's commitment to driving innovation and growth.

Despite the positive outlook, investors should remain aware of potential risks, including the company's cash burn rate and the competitive landscape in the oncology market. Senti Biosciences has a market capitalization of $90.6 million and a current ratio of 4.22, indicating strong liquidity, but it is quickly burning through cash [1].

References:
[1] https://in.investing.com/news/analyst-ratings/laidlaw-initiates-coverage-on-senti-biosciences-stock-with-buy-rating-93CH-4865963
[2] https://www.gurufocus.com/news/2912370/senti-bio-snti-receives-buy-rating-from-laidlaw-with-5-target-snti-stock-news